MedTrace Logo

Endovascular Treatment With Versus Without Intravenous rhTNK-tPA in Stroke

NCT04733742 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 550

Last updated 2025-04-03

No results posted yet for this study

Summary

The purpose of this trial is to investigate whether intravenous rhTNK-tPA prior to endovascular treatment can improve 90-day functional outcome of stroke patients with large vessel occlusion who are thrombolysis-eligible within 4.5 hours of symptom onset.

Conditions

  • Stroke, Acute
  • Stroke, Ischemic

Interventions

DRUG

rhTNK-tPA

intravenous thrombolysis with rhTNK-tPA followed by endovascular treatment

OTHER

Endovascular treatment

endovascular treatment

Sponsors & Collaborators

  • CSPC RECOMGEN PHARMACEUTICAL (GUANGZHOU) CO.,LTD

    collaborator UNKNOWN

  • Xinqiao Hospital of Chongqing

    lead OTHER

Principal Investigators

  • Qingwu Yang, MD · Neurology, Xinqiao Hospital of the Army Medical University

  • Raul G Nogueira, MD · Marcus Stroke & Neuroscience Center, Grady Memorial Hospital, Emory University, Atlanta, USA

  • Jeffrey L Saver, MD · Neurology, University of California, Los Angeles, USA

  • Wenjie Zi, MD · Neurology, Xinqiao Hospital of the Army Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-09
Primary Completion
2024-12-16
Completion
2025-02-07

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04733742 on ClinicalTrials.gov